Pharmaceutical Research Overview
Eprex 0.5ml 2000 IU Janssen-Cilag is a pharmaceutical-grade recombinant human erythropoietin (EPO) preparation manufactured by Janssen-Cilag for laboratory research applications. This glycoprotein hormone preparation enables researchers at Stroid UK Shop to investigate erythropoiesis mechanisms, hematopoietic stem cell differentiation pathways, and cellular responses to hypoxic stress conditions in controlled laboratory environments.
Laboratory Investigation Applications
Research scientists utilise this EPO formulation to examine red blood cell production mechanisms, study bone marrow cell culture responses, and investigate the molecular pathways involved in oxygen-sensitive gene expression. The preparation allows for detailed analysis of EPO receptor binding kinetics, downstream signalling cascades, and cellular proliferation responses in haematopoietic cell lines. Comparative studies with other hormone drugs frequently incorporate this EPO preparation as a positive control in cell culture experiments examining growth factor responses and cellular differentiation protocols.
Technical Specifications
| Active Ingredient | Recombinant Human Erythropoietin |
|---|---|
| Concentration | 2000 IU per 0.5ml |
| Manufacturer | Janssen-Cilag |
| Form | Injectable Solution |
| Volume | 0.5ml |
| Storage | 2-8°C, Refrigerated |
| Molecular Weight | Approximately 30.4 kDa |
| Shelf Life | Per manufacturer specifications |
Laboratories studying peptide hormone mechanisms often cross-reference EPO research with peptides investigations, while researchers examining growth factor interactions may incorporate complementary studies using SARMs compounds to understand receptor-mediated signalling pathways across different molecular targets.
Research Compliance Statement
This Eprex 0.5ml 2000 IU Janssen-Cilag preparation is supplied exclusively for in-vitro laboratory research purposes. This product is not intended for human consumption, therapeutic use, or any clinical application. Researchers must ensure appropriate biosafety protocols, proper waste disposal procedures, and compliance with institutional guidelines when handling this recombinant protein preparation in laboratory settings.
